Celecoxib (Celebrex)
celecoxib
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Osteoarthritis | Adults | Monotherapy | FDA Approved |
| Rheumatoid arthritis | Adults | Monotherapy or adjunctive with DMARDs | FDA Approved |
| Juvenile rheumatoid arthritis | ≥2 years | Monotherapy or adjunctive | FDA Approved |
| Ankylosing spondylitis | Adults | Monotherapy | FDA Approved |
| Acute pain | Adults | Monotherapy | FDA Approved |
| Primary dysmenorrhea | Adults | Monotherapy | FDA Approved |
Celecoxib is the first and only COX-2 selective NSAID that remains on the US market following the withdrawal of rofecoxib and valdecoxib. Its selective inhibition of COX-2 over COX-1 was designed to preserve the gastrointestinal protective prostaglandins produced by COX-1, while still suppressing inflammation-driven prostaglandin synthesis. The PRECISION trial (2016) demonstrated that celecoxib 100 mg BID was non-inferior to naproxen and ibuprofen for the composite cardiovascular endpoint. Celecoxib is a sulfonamide derivative and is contraindicated in patients with sulfonamide allergy.
Familial adenomatous polyposis (FAP) — Celecoxib 400 mg BID was previously FDA-approved as an adjunct to usual care for reduction of colorectal polyps in FAP. This indication was voluntarily withdrawn by the manufacturer in 2011 but remains used off-label in select patients. Evidence quality: Moderate.
Acute migraine — An oral solution formulation (Elyxyb 120 mg) is FDA-approved for acute migraine with or without aura; capsule formulations are used off-label for this purpose. Evidence quality: High.
Perioperative pain (multimodal analgesia) — Celecoxib 200–400 mg preoperatively is widely used as part of Enhanced Recovery After Surgery (ERAS) protocols to reduce opioid consumption. Evidence quality: Moderate.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Osteoarthritis — chronic symptom management | 200 mg once daily or 100 mg BID | 200 mg/day | 200 mg/day | Once-daily dosing provides comparable efficacy to divided dosing; may be given without regard to meals Use lowest effective dose for shortest duration |
| Rheumatoid arthritis — active disease | 100 mg BID | 100–200 mg BID | 400 mg/day | Titrate based on response; 200 mg BID may be required in active disease Does not alter disease course; use alongside DMARDs |
| Ankylosing spondylitis — initial trial | 200 mg once daily or 100 mg BID | 200 mg/day | 400 mg/day | If no response at 200 mg/day after 6 weeks, trial 400 mg/day; if no response after further 6 weeks, unlikely to respond Assess before escalating and before continuing |
| Acute pain / primary dysmenorrhea | 400 mg × 1 Then 200 mg if needed on day 1 | 200 mg BID | Day 1: 600 mg; thereafter 400 mg/day | Use for shortest duration necessary; onset of analgesia typically within 1 h of first dose |
| Perioperative analgesia (off-label, ERAS) | 200–400 mg preoperatively | 200 mg BID × 3–5 days | 400 mg/day | Part of multimodal opioid-sparing strategy; not for use in CABG or within 10–14 days of cardiac surgery Verify renal function and haemodynamic status preoperatively |
Pediatric Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| JRA (≥2 years, 10–25 kg) | 50 mg BID | 50 mg BID | 100 mg/day | Capsule contents may be sprinkled on applesauce for children who cannot swallow capsules; ingest immediately with water Monitor for DIC risk in systemic-onset JRA |
| JRA (≥2 years, >25 kg) | 100 mg BID | 100 mg BID | 200 mg/day | Safety not studied beyond 6 months; long-term CV toxicity in children not evaluated Consider alternative treatment in CYP2C9 poor metabolisers |
Celecoxib is predominantly metabolised by CYP2C9. Patients who are CYP2C9 poor metabolisers (e.g., *3/*3 genotype, ~1–3% of Caucasians) have 3–7 fold higher celecoxib exposure and should start at 50% of the lowest recommended dose. For JRA patients who are known or suspected poor CYP2C9 metabolisers, the FDA PI recommends considering alternative treatments rather than dose adjustment. Pre-treatment genotyping is not mandatory but should be considered in patients with unexpectedly prolonged drug effect or known CYP2C9 variant history (e.g., warfarin or phenytoin sensitivity).
Special Population Adjustments
| Population | Adjustment | Rationale |
|---|---|---|
| Moderate hepatic impairment (Child-Pugh B) | Reduce daily dose by 50% | AUC increased ~180% vs. healthy controls; risk of accumulation and hepatotoxicity |
| Severe hepatic impairment (Child-Pugh C) | Not recommended; avoid use | No clinical data; expected marked increase in exposure |
| CYP2C9 poor metabolisers | Start at 50% of lowest recommended dose (adults); consider alternatives (JRA) | 3–7 fold increased AUC; risk of dose-dependent adverse effects |
| Advanced renal disease | Not recommended | No controlled data; may hasten renal dysfunction progression |
| Elderly (≥65 years) | Use lowest effective dose; no specific dose reduction unless hepatic/renal impairment | Increased susceptibility to GI, CV, and renal adverse events |
Pharmacology
Mechanism of Action
Celecoxib is a diaryl-substituted pyrazole derivative that selectively inhibits cyclooxygenase-2 (COX-2) at therapeutic concentrations while largely sparing COX-1 activity. COX-2 is the inducible isoform upregulated at sites of inflammation, where it drives prostaglandin synthesis responsible for pain, swelling, and fever. By selectively targeting COX-2, celecoxib reduces inflammatory prostaglandin production without substantially inhibiting the COX-1-dependent gastric mucosal prostaglandins that protect the stomach lining. However, COX-2 selectivity also means reduced thromboxane A2 suppression relative to non-selective NSAIDs, while prostacyclin (PGI2) production is still inhibited, which is proposed as one mechanism for the cardiovascular risk observed with coxibs at supra-therapeutic doses. Celecoxib also contains a sulfonamide moiety, making it contraindicated in patients with sulfonamide hypersensitivity.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Tmax ~3 h; dose-proportional up to 200 mg BID; less than proportional at higher doses; food increases AUC 10–20% and delays Tmax by 1–2 h | Can be taken with or without food; high-fat meal may modestly increase exposure; low solubility prolongs absorption and contributes to variable terminal half-life |
| Distribution | Apparent Vd ~400 L; ~97% albumin-bound; penetrates synovial fluid and CNS | Extensive tissue distribution despite high protein binding; crosses into breast milk at very low levels (~0.3% of maternal dose) |
| Metabolism | CYP2C9 (major, ~75%); CYP3A4 (minor, <25%); to hydroxycelecoxib → carboxycelecoxib → glucuronide; all metabolites inactive; inhibits CYP2D6 | CYP2C9 poor metabolisers have 3–7× higher exposure (reduce dose 50%); CYP2C9 inhibitors (e.g., fluconazole) double AUC; monitor CYP2D6 substrates (e.g., metoprolol) for toxicity |
| Elimination | t½ ~11 h (fasted); 57% faeces, 27% urine (as metabolites); <3% unchanged; steady state by day 5 | Supports BID dosing for sustained effect; hepatic impairment markedly increases AUC (40% mild, 180% moderate); low renal excretion but metabolite accumulation possible in renal failure |
Side Effects
Data from 12 pre-marketing controlled trials in ~4,250 OA and ~2,100 RA patients, plus >8,500 patients who received celecoxib ≥200 mg/day. Over 3,900 patients were treated for ≥6 months and ~2,300 for ≥1 year (FDA PI, revised 11/2024). Note: headache was reported in 15.8% of celecoxib patients but was actually lower than placebo (20.2%) and is not considered a drug-related adverse effect.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dyspepsia | 8.8% (vs 6.2% placebo) | Most common GI complaint; significantly lower than naproxen (12.2%), diclofenac (10.9%), and ibuprofen (12.8%) in head-to-head comparisons |
| Upper respiratory infection | 8.1% (vs 6.7% placebo) | May reflect COX-2 inhibition affecting mucosal immune function; usually self-limiting |
| Diarrhoea | 5.6% (vs 3.8% placebo) | Dose-related; evaluate for GI complications if persistent |
| Sinusitis | 5.0% (vs 4.3% placebo) | Common in long-term arthritis trials; similar frequency to comparator NSAIDs |
| Abdominal pain | 4.1% (vs 2.8% placebo) | Lower than naproxen (7.7%), diclofenac (9.0%), and ibuprofen (9.0%); evaluate if worsening or persistent |
| Nausea | 3.5% (vs 4.2% placebo) | Lower than placebo; not considered drug-related; take with food if troublesome |
| Accidental injury | 2.9% (vs 2.3% placebo) | Possibly related to underlying arthritis or concurrent dizziness |
| Back pain | 2.8% (vs 3.6% placebo) | Lower than placebo; likely related to underlying condition |
| Pharyngitis | 2.3% (vs 1.1% placebo) | Usually self-limiting |
| Insomnia | 2.3% (vs 2.3% placebo) | Equal to placebo; not drug-related |
| Flatulence | 2.2% (vs 1.0% placebo) | Lower than naproxen (3.6%) and comparator NSAIDs |
| Rash | 2.2% (vs 2.1% placebo) | Discontinue immediately if progressing; rule out SJS/TEN/DRESS |
| Peripheral edema | 2.1% (vs 1.1% placebo) | Monitor weight and blood pressure; 4.5% at 400 mg BID in CLASS trial |
| Dizziness | 2.0% (vs 1.7% placebo) | Advise caution with driving at treatment initiation |
| Rhinitis | 2.0% (vs 1.3% placebo) | Generally mild and self-limiting |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Cardiovascular thrombotic events (MI, stroke) | Dose-dependent: HR 2.8 at 200 mg BID, HR 3.4 at 400 mg BID vs. placebo (APC trial); non-inferior to tNSAIDs at 100 mg BID (PRECISION) | May begin within first weeks; increases with dose and duration | Use lowest effective dose for shortest duration; avoid post-CABG; monitor CV symptoms; contraindicated in recent MI unless benefits outweigh risk |
| GI bleeding, ulceration, perforation | 0.78% at 9 months (CLASS); 2.19% if on ASA | Any time; without warning | Discontinue; urgent endoscopy; GI rate lower than tNSAIDs in CLASS but not zero, especially with concurrent aspirin |
| Hepatotoxicity (severe) | Rare; borderline LFT elevation in 6% (vs 5% placebo); notable elevation (ALT/AST ≥3× ULN) in 0.2% | Weeks to months | Discontinue if symptomatic LFT elevation or ≥3× ULN; hepatic workup; permanent discontinuation if severe |
| Acute kidney injury / renal papillary necrosis | Uncommon; elevated BUN more frequent than placebo | Days to weeks; especially with dehydration or concurrent nephrotoxics | Discontinue; IV hydration; monitor creatinine; correct volume depletion before initiating |
| Severe skin reactions (SJS, TEN, DRESS, AGEP) | Very rare | 1–8 weeks; DRESS may present as viral infection | Discontinue immediately at first sign of rash or hypersensitivity; dermatology referral; permanent discontinuation |
| Anaphylaxis / anaphylactoid reactions | Very rare; increased risk in sulfonamide-allergic patients | Minutes to hours | Emergency management; permanent discontinuation of celecoxib and all NSAIDs |
| Heart failure exacerbation | ~2-fold increased hospitalisation risk (NSAID class) | Days to weeks | Avoid in severe HF; monitor fluid balance; discontinue if decompensation occurs |
| Disseminated intravascular coagulation (DIC) | Rare; specific risk in systemic-onset JRA | Variable | Monitor coagulation parameters in systemic JRA; discontinue if signs of DIC; supportive care |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Dyspepsia | 0.8% | vs 0.6% placebo; most common reason |
| Abdominal pain | 0.7% | vs 0.6% placebo |
| Nausea | Not individually quantified | Nausea occurred in 3.5% overall (lower than placebo 4.2%); contributed to a small number of discontinuations but was not among the individually reported reasons in the PI |
| Rash / hypersensitivity | <1% | Mandates discontinuation if concerning for serious skin reaction |
Celecoxib’s COX-2 selectivity results in fewer upper GI complications compared to non-selective NSAIDs when used alone. However, this advantage is substantially reduced when celecoxib is combined with low-dose aspirin for cardiovascular prophylaxis. In the CLASS trial, symptomatic ulcer rates at 9 months were 0.78% overall but rose to 2.19% in the subgroup taking concomitant low-dose aspirin, and 3.06% in patients ≥65 years also on aspirin. Consider gastroprotective therapy with a PPI for any patient combining celecoxib with aspirin.
Drug Interactions
Celecoxib is a CYP2C9 substrate and a CYP2D6 inhibitor. It does not significantly interact with warfarin pharmacokinetically, but the pharmacodynamic synergy on bleeding risk is clinically important. Unlike non-selective NSAIDs, celecoxib does not interfere with the antiplatelet effect of aspirin at doses of 100–325 mg daily.
Monitoring
- Blood PressureBaseline, then every 2–4 weeks initially
RoutineNSAIDs including celecoxib can raise BP. PRECISION trial found mean systolic increase of 0.2 mmHg with celecoxib 100 mg BID vs. 1.7 mmHg with ibuprofen. Monitor more frequently in patients on antihypertensives. - Renal FunctionBaseline, then q6–12 months
RoutineSerum creatinine, BUN, eGFR. Elevated BUN was more frequent with celecoxib vs. placebo in trials. Check within 1–2 weeks in high-risk patients (elderly, dehydrated, on RAAS inhibitors). - Hepatic FunctionBaseline; then if symptoms
Trigger-basedALT/AST. Borderline elevations (≥1.2× and <3× ULN) occurred in 6% of celecoxib patients vs. 5% placebo. Discontinue if ≥3× ULN or symptomatic. - CBCBaseline; then if signs of anaemia or bleeding
Trigger-basedAnaemia incidence 0.6% vs. 0.4% placebo. Check if unexplained fatigue, pallor, or dark stools develop. - GI SymptomsEvery visit
RoutineAsk about dyspepsia, abdominal pain, melena, haematemesis. COX-2 selectivity reduces but does not eliminate GI risk, especially with concomitant aspirin. - CV SymptomsEvery visit
RoutineScreen for chest pain, dyspnoea, fluid retention. Reassess risk-benefit periodically. Dose-dependent CV risk was demonstrated in the APC trial at supra-therapeutic doses. - Coagulation (JRA)Baseline and periodically in systemic-onset JRA
Trigger-basedMonitor PT/INR, fibrinogen, D-dimer for signs of DIC in patients with systemic-onset JRA. Educate caregivers on bruising and bleeding signs.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to celecoxib or any component, including history of anaphylaxis or serious skin reactions
- Known sulfonamide allergy — celecoxib contains a sulfonamide moiety; cross-reactivity may occur
- Aspirin-exacerbated respiratory disease (AERD) — history of asthma, urticaria, or allergic reactions triggered by aspirin or other NSAIDs
- Peri-operative CABG surgery setting — increased risk of MI and stroke
- Pregnancy ≥30 weeks gestation — risk of premature ductus arteriosus closure and fetal renal dysfunction
Relative Contraindications (Specialist Input Recommended)
- Severe hepatic impairment (Child-Pugh C) — no clinical data; marked exposure increase expected
- Advanced renal disease — may hasten renal dysfunction; use only if benefits clearly outweigh risk
- Active peptic ulcer or recent GI bleed — requires specialist co-management and mandatory PPI
- Severe heart failure (NYHA III–IV) — risk of decompensation; ~2-fold increased hospitalisation
- Pregnancy 20–30 weeks — FDA recommends limiting NSAID use; risk of oligohydramnios
- CYP2C9 poor metabolisers — JRA population — FDA recommends considering alternative treatments
Use with Caution
- Elderly (≥65 years) — increased GI, CV, and renal adverse event risk; start at lowest dose
- Known cardiovascular disease or multiple CV risk factors — use lowest dose/shortest duration; supra-therapeutic doses increase risk (APC trial)
- Moderate hepatic impairment (Child-Pugh B) — reduce dose by 50% (AUC ~180% higher)
- Concurrent CYP2C9 inhibitors (fluconazole, amiodarone) — reduces celecoxib clearance; halve dose
- Concurrent anticoagulants, SSRIs, or corticosteroids — additive bleeding risk
- History of asthma (without aspirin sensitivity) — monitor for exacerbation
- Systemic-onset JRA — risk of DIC; monitor coagulation parameters
Cardiovascular Thrombotic Events: NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may begin early in treatment and increase with duration of use. Celecoxib is contraindicated in the setting of CABG surgery. In the APC trial, celecoxib showed dose-dependent CV risk: HR 2.8 (200 mg BID) and HR 3.4 (400 mg BID) for the composite endpoint of CV death, MI, or stroke compared to placebo.
Gastrointestinal Bleeding, Ulceration, and Perforation: NSAIDs cause an increased risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use without warning. Elderly patients and those with prior peptic ulcer disease or GI bleeding are at greater risk.
Patient Counselling
Purpose of Therapy
Celecoxib reduces pain, swelling, and stiffness by blocking a specific inflammation-producing enzyme (COX-2) while being gentler on the stomach than older anti-inflammatory drugs. It is not a cure for arthritis but helps manage symptoms so that daily activities become more comfortable. The medication should be taken at the lowest effective dose for the shortest time needed.
How to Take
Swallow capsules whole with water. May be taken with or without food, but taking with food may reduce stomach upset. For children who cannot swallow capsules, the contents may be sprinkled onto a level teaspoon of cool or room-temperature applesauce and swallowed immediately with water. Do not combine with other NSAID products (ibuprofen, naproxen, aspirin for pain). If you miss a dose, take it as soon as remembered unless it is close to the next scheduled dose; do not double up.
Sources
- Celebrex (celecoxib) capsules — Full Prescribing Information. Revised 11/2024. U.S. FDA Reference ID: 5482829. accessdata.fda.govPrimary source for all approved indications, dosing, adverse reactions (Table 1), contraindications, and boxed warning cited throughout this monograph.
- Elyxyb (celecoxib) oral solution — Full Prescribing Information. Revised 2024. accessdata.fda.govSource for oral solution formulation data and acute migraine indication details.
- Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–2529. doi:10.1056/NEJMoa1611593The PRECISION trial (N=24,081): celecoxib 100 mg BID was non-inferior to naproxen and ibuprofen for major adverse cardiovascular events, with lower GI event rates.
- Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. JAMA. 2000;284(10):1247–1255. doi:10.1001/jama.284.10.1247Landmark GI safety trial; source for symptomatic ulcer rates (0.78% overall; 2.19% with aspirin) at 9 months and peripheral edema data.
- Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9):873–884. doi:10.1056/NEJMoa061355The APC trial; demonstrated ~3-fold increased CV risk at celecoxib 200–400 mg BID vs. placebo, establishing the dose-dependent CV risk profile.
- Bhala N, Emberson J, Merhi A, et al. (CNT Collaboration). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs. Lancet. 2013;382(9894):769–779. doi:10.1016/S0140-6736(13)60900-9Individual participant data meta-analysis; source for NSAID-class CV and GI risk estimates including heart failure hospitalisation data.
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2020;72(2):149–162. doi:10.1002/acr.24131Conditionally recommends oral NSAIDs including celecoxib for OA; advises lowest effective dose and shortest duration.
- Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–738. doi:10.1038/ajg.2009.115Key guideline for GI risk stratification and gastroprotective co-therapy with NSAIDs including COX-2 selective agents.
- FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345(6):433–442. doi:10.1056/NEJM200108093450607Seminal review of COX-2 selectivity, prostacyclin-thromboxane balance, and the mechanistic basis of coxib cardiovascular risk.
- Gong L, Thorn CF, Bertagnolli MM, et al. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22(4):310–318. doi:10.1097/FPC.0b013e32834f94cbComprehensive pharmacogenomics and pharmacokinetic pathway review; source for CYP2C9 metabolism data and CYP2D6 inhibition documentation.
- Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38(3):225–242. doi:10.2165/00003088-200038030-00003Definitive PK review covering absorption, protein binding (~97%), Vd (~455 L), hepatic/renal impairment effects, and drug interactions.
- Gardiner SJ, Doogue MP, Zhang M, Begg EJ. Quantification of infant exposure to celecoxib through breast milk. Br J Clin Pharmacol. 2006;61(1):101–104. doi:10.1111/j.1365-2125.2005.02520.xKey lactation study; infant dose ~0.23% of maternal dose; supports compatibility with breastfeeding at routine doses.
- Brutzkus JC, Shahrokhi M, Engel A. Celecoxib. In: StatPearls. Treasure Island, FL: StatPearls Publishing; Updated Feb 28, 2024. ncbi.nlm.nih.govComprehensive clinical overview including dosing across indications, CYP2C9 poor metaboliser guidance, and monitoring recommendations.
- Tang C, Shou M, Mei Q, et al. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib. Drug Metab Dispos. 2000;28(3):308–314. PubMed: 10681375In vitro study establishing CYP2C9 as the major enzyme responsible for celecoxib hydroxylation, and the role of CYP2C9 polymorphisms in celecoxib exposure variability.